430 related articles for article (PubMed ID: 32315324)
1. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
[TBL] [Abstract][Full Text] [Related]
2. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M
Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408
[TBL] [Abstract][Full Text] [Related]
3. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
4. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
5. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
6. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
7. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA Harboring the
Sato A; Tanabe M; Tsuboi Y; Niwa T; Shinozaki-Ushiku A; Seto Y; Murakami Y
Thyroid; 2021 Dec; 31(12):1822-1828. PubMed ID: 34541884
[No Abstract] [Full Text] [Related]
10. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma.
Lu J; Gao J; Zhang J; Sun J; Wu H; Shi X; Teng L; Liang Z
Int J Clin Exp Pathol; 2015; 8(1):793-9. PubMed ID: 25755776
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
[TBL] [Abstract][Full Text] [Related]
12. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
13. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
[TBL] [Abstract][Full Text] [Related]
14. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
[TBL] [Abstract][Full Text] [Related]
15. Predicting factors of central lymph node metastasis and BRAF
Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF
World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769
[TBL] [Abstract][Full Text] [Related]
16. Integrating BRAF
Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
[TBL] [Abstract][Full Text] [Related]
17. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
18. Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer.
Li R; Hao J; Zhu Z; Qiao X; Wang L; Zhou Z
Biomed Res Int; 2021; 2021():9937742. PubMed ID: 34307677
[TBL] [Abstract][Full Text] [Related]
19. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
20. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
